4th International Symposium

Vitamin D and Analogs in Cancer Prevention and Therapy

Organized by J. Reichrath, M. Friedrich and T. Vogt

May 20-21, 2011

Department of Dermatology, Venerology and Allergology,
The Saarland University Hospital, Homburg/Saar, Germany

and

Klinik für Frauenheilkunde
und Geburtshilfe des Klinikums Krefeld, Germany

PRELIMINARY PROGRAMME
Organizing Committee

J. Reichrath¹
M. Friedrich²
T. Vogt¹

¹Department of Dermatology, Venerology and Allergology, The Saarland University Hospital, Homburg/Saar, Germany and ²Klinik für Frauenheilkunde und Geburtshilfe des Klinikums Krefeld, Germany.

Scientific Board

C. Carlberg, Kuopio
D. Feldman, Stanford
M. Friedrich, Krefeld
M.F. Holick, Boston
J. Reichrath, Homburg/Saar
T. Vogt, Homburg/Saar
WELCOME ADDRESS

Dear participants, colleagues and friends!

On behalf of the scientific committee it is a pleasure to welcome you as our guests here in Homburg on the occasion of the 4th International Symposium entitled Vitamin D and Analogs in Cancer Prevention and Therapy. During the past years our knowledge about molecular biology, metabolism and biologic effects of vitamin D analogs has exploded. These findings have lead to new concepts for the prevention and treatment of various types of cancer by vitamin D and analogs, and it is obvious that enormous scientific progress is being made on this topic. This meeting is specially designed to offer scientists and clinicians insights into the latest developments in this intriguing research area, both basic and clinical. Keynote lectures include skin cancer, breast cancer, prostate cancer and colorectal cancer.

We wish you a pleasant stay, and hope you will enjoy this meeting as well as the social programme.

Jörg Reichrath         Michael Friedrich         Thomas Vogt
CONGRESS INFORMATION

Congress Office
Dorothee Neurohr
Annett Weinhold
Department of Dermatology
The Saarland University Hospital
66421 Homburg/Saar, Germany
Phone: 0049-6841-1623832
Fax: 0049-6841-1623830
E-Mail: dorothee.neurohr@uks.eu

During the symposium the congress office is placed at the Schlossberg Hotel
Homburg/Saar

Location
The symposium is held at the Schlossberg Hotel Homburg/Saar, Germany
Phone: +49 6841-6660; Fax: +49-6841-620 18

Desks
From Friday, May 20 at 7.30 a.m. The following desks will be situated at the Schlossberg Hotel:
Registration/Information/Secretariat/Projection

Conference Language
English

Presentation
Speakers are requested to turn their Power point presentations over to the projectionist at least 15 minutes before the session begins.
Social Programme

The organizers invite all speakers and registered participants on Thursday evening (6.30 PM) to a welcome reception at the Schlossberghöhlen (3 min walk from the Schlossberg Hotel) and on Friday for lunch at the Schlossberg Hotel. There will be a sightseeing tour to the old roman capitol Trier on Saturday afternoon/evening for which a limited number of tickets (80 EURO/person) can be purchased at the registration desk. Busses will leave in front of the Schlossberg Hotel at 3.30 PM and will be back around midnight. Additionally, tickets for dinner on Friday evening (55 EURO/person) and for Lunch on Saturday (30 EURO/person) can be purchased at the registration desk.
PRELIMINARY PROGRAMME

Friday, May 20

7.30 AM – 6.00 PM    Registration

Featured Lectures

8.00 – 8.05 AM    N.N.: Welcome address

8.05 – 8.15 AM    J. Reichrath (Homburg) and M. Friedrich (Krefeld):
Opening remarks.

I. Historic and Future Perspectives of Vitamin D
Chairpersons:    D. Feldman (Palo Alto, USA),
                T. Vogt (Homburg, Germany)

8.15 – 8.45 AM    M. F. Holick, Boston, USA:
The D-lightful Vitamin D for Health.
(25 + 5 min, Abstract No. 1)

II. Molecular Biology of Vitamin D: Implications for Cancer (I)
Chairpersons:    D. Feldman (Palo Alto, USA),
                T. Vogt (Homburg, Germany)

8.45 – 9.15 AM    J. W. Pike, Madison, USA:
New Paradigms for Gene Regulation by 1,25-Dihydroxyvitamin D₃.
(25 + 5 min, Abstract No. 2)
9.15 – 9.45 AM  **C. Carlberg, Luxembourg:**
A genome-wide perspective on vitamin D signalling.
*(25 + 5 min, Abstract No. 3)*

9.45 -10.00 AM  **N. Rochel, Illkirch, France:**
Solution structures of nuclear receptor heterodimers.
*(12 + 3 min, Abstract No. 4).*

10.00 – 10.30 AM  **M. R. Haussler, Tucson, USA:**
The Vitamin D Receptor: The Fountain of Youth in Cancer Prevention.
*(25 + 5 min, Abstract No. 5)*

10.30 – 11.00 PM  **Coffee Break, Industrial Exhibition,**
**and Poster viewing**

**III. Molecular Biology of Vitamin D: Implications for Cancer (II)**
Chairpersons:  **J. W. Pike (Madison, USA),**
               **F. Lammert (Homburg, Germany)**

11.00 – 11.30 AM  **A. Muñoz, Madrid, Spain:**
Vitamin D and colon cancer: Regulation and effects of *SPROUTY-2* and *DICKKOPF-1* genes and proteomic analysis.
*(25 + 5 min, Abstract No. 6)*

11.30 – 12.00 AM  **G. Jones, Kingston, Canada:**
New insights into the role of CYP24A1 in vitamin D metabolism.
*(25 + 5 min, Abstract No. 7)*

00.00 – 0.30 PM  **D. Feldman, Palo Alto, USA:**
Calcitriol actions in breast cancer.
*(25 + 5 min, Abstract No. 8)*
0.30 – 1.45 PM  
Lunch Break, Industrial Exhibition,  
and Poster viewing

IV. Molecular Biology of Vitamin D: Implications for Cancer (III)  
Chairpersons: M. R. Haussler (Tucson, USA),  
U. Mahlknecht (Homburg, Germany)

1.45 – 2.05 PM  
I. N. Sergeev, Brookings, USA:  
Vitamin D and Calcium Signalling in Cancer.  
(17 + 3 min, Abstract No. 9)

2.05 – 2.15 PM  
D. Salehin, Krefeld, Germany:  
The vitamin D endocrine system in in squamous epithelial vulvar  
cancer and vulvar intraepithelial neoplasia.  
(7 + 3 min, Abstracts No. 10 + 11)

2.15 – 2.25 PM  
N. Lopes, Porto, Portugal:  
1alpha,25-dihydroxyvitamin D3 Induces the de novo Expression  
of E-cadherin in MDA-MB-231 Breast Cancer Cells.  
(7 + 3 min, Abstract No.12)

2.25 – 2.35 PM  
M. Thill, Lübeck, Germany:  
Influence of calcitriol on PG- and vitamin D-metabolising  
enzymes in benign and malignant breast cancer cell lines.  
(7 + 3 min, Abstract No. 13)

2.35 – 2.45 PM  
T. Cordes, Lübeck, Germany:  
Correlation of prostaglandin metabolising enzymes and PGE2  
serum levels with vitamin D receptor and 25(OH)2D3 serum levels  
in breast and ovarian cancer.  
(7 + 3 min, Abstract No.14)
2.45 – 2.55 PM  **B. Li, Suzhou, China:**
The Combined Effect of 1,25(OH)₂D₃ with CBP or Ionizing Radiation on Proliferation of Ovarian Cancer SKOV-3 Cells.
*(7 + 3 min, Abstract No. 15)*

2.55 – 3.25 PM  **D. Trump, Buffalo, USA:**
Randomized study of 4000 IU, 6000 IU, 8000 IU or 10,000 IU of cholecalciferol in men with prostate cancer: toxicity and 25(OH)D₃ effects.
*(25 + 5 min, Abstract No. 16)*

3.25 – 3.55 PM  **R. Vieth, Toronto, Canada:**
High-dose oral vitamin D₃ administration to prostate cancer patients increases intra-prostate levels of vitamin D metabolites.
*(25 + 5 min, Abstract No. 17)*

3.55 – 4.10 PM  **T. C. Chen, Boston, USA:**
New Insights into the Roles of Cytochrome P-450 Enzymes in Prostate Cancer.
*(12 +3 min, Abstract No. 18)*

4.10 – 4.20 PM  **F. Bremmer, Göttingen, Germany:**
Expression and function of the Vitamin D receptor in malignant germ cell tumour of the testis.
*(7 + 3 min, Abstract No. 19)*

4.20 – 4.50 PM  **Coffee Break, Industrial Exhibition, and Poster viewing**
V. Molecular Biology of Vitamin D: Implications for Cancer (IV)

Chairpersons:  
A. Muñoz (Madrid, Spain),  
M. F. Holick, (Boston, USA)

4.50 – 5.15 PM  
C. S. Johnson, Buffalo, USA:  
Calcitriol-mediated antitumor effects: the role in human bladder cancer.  
(20 + 5 min, Abstract No. 20)

5.15 – 5.25 PM  
J. Reichrath, Homburg, Germany:  
Serum levels of 25(OH)D and VDR polymorphisms in malignant melanoma: results from pilot studies in Homburg.  
(7 + 3 min, Abstract No. 21)

5.25 – 5.35 PM  
S. Essa, Homburg, Germany:  
Signatures of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines.  
(7 + 3 min, Abstract No. 22)

5.35 – 6.05 PM  
J. A. Newton-Bishop, Leeds, UK:  
The determinants of serum vitamin D levels in participants in a melanoma case-control study living in a temperate climate.  
(25 + 5 min, Abstract No. 23)

6.05 – 6.25 PM  
A. Uhmann, Göttingen, Germany:  
Antitumoral effects of calcitriol in Patched1-associated basal cell carcinomas involve inhibition of Hedgehog-signaling and induction of differentiation.  
(17 + 3 min, Abstract No. 24)

6.25 – 6.35 PM  
R. Norton, Norwich, UK:  
Immunomodulatory effects of 1,25(OH)₂D₃ in normal and transformed human lung epithelium.  
(7 + 3 min, Abstract No. 25)
6.35 – 7.00 PM  H. Sigmundsdottir, Reykjavik, Iceland:
Vitamin D, the immune system and cancer.
(20 + 5 min, Abstract No. 26)

Arnold-Rikli-Price 2011

Saturday, May 21

8.00 AM - 1.20 PM

VI  New Vitamin D Analogs
Chairpersons:  G. Jones (Toronto, Canada),
      M. Friedrich (Krefeld, Germany)

8.00 – 8.15 AM  N. Kubodera, Tokyo, Japan:
Process developments for the practical production of eldecalcitol
by linear synthesis, convergent synthesis, and biomimetic synthesis.
(12 + 3 min, Abstract No. 27)

8.15 – 8.30 AM  A. Kittaka, Kanagawa, Japan:
Synthesis of C15-Modified 16-ene-active vitamin D₃ analogs for
the receptor-ligand interaction studies.
(12 + 3 min, Abstract No. 28)

8.30 – 8.45 AM  T. Fujishima, Kagawa, Japan:
Novel vitamin D receptor ligands having a carboxyl group as a
possible anchor to the crucial arginine residue in the ligand-
binding domain.
(12 + 3 min, Abstract No. 29)
8.45 – 9.00 AM  D. Sawada, Kanagawa, Japan:
Evaluation and characterization of 14-epi-19-nortachysterol
analogs from 14-epi-19-norprevitamin D₃.
(12 + 3 min, Abstract No. 30)

VII.  Vitamin D in Cancer Prevention (I)
Chairpersons:  R. Vieth (Toronto, Canada),
               J. Reichrath (Homburg, Germany)

9.00 – 9.30 AM  H. Brenner, Heidelberg, Germany:
Vitamin D and cancer: an overview on epidemiological studies.
(25 + 5 min, Abstract No. 31)

9.30 – 10.00 AM  W. B. Grant, San Francisco, USA:
Ecological Study Findings Regarding Vitamin D and Cancer.
(25 + 5 min, Abstract No. 32)

10.00 – 10.30 AM  Coffee Break, Industrial Exhibition,
                   and Poster viewing

VII.  Vitamin D in Cancer Prevention (II)
Chairpersons:  R. Vieth (Toronto, Canada),
               D. Trump (Buffalo, USA)

10.30 – 11.00 AM  J. Moan, Oslo, Norway:
Is sunshine and vitamin D protective against melanoma on
shielded sites?
(25 + 5 min, Abstract No. 33)

11.00 – 11.15 AM  A. Juzeniene, Oslo, Norway:
The role of month of diagnosis for cancer prognosis.
(12 +3 min, Abstract No. 34)
11.15 – 11.30 AM  **R. Krause, Berlin, Germany:**
Cancer Mortality in End-stage Kidney Disease Patients is independent from Vitamin D Status.
*(12 + 3 min, Abstract No. 35)*

11.30 – 11.45 AM  **J. Mahlstedt, Essen, Germany:**
Vitamin D-Deficiency / Sec. Hyperparathyroidism and the Seasonal Changes in Germany *(51° Latitude).*
*(12 + 3 min, Abstract No. 36)*

11.45 – 12.00 AM  **A. Zittermann, Bad Oeynhausen, Germany:**
Vitamin D Status and Cardiovascular Disease.
*(12 + 3 min, Abstract No. 37)*

0.00 – 0.15 PM  **P. Tuohimaa, Tampere, Finland:**
An optimal serum calcidiol concentration for cancer prevention.
*(12 + 3 min, Abstract No. 38)*

0.15 – 0.45 PM  **M. F. Holick, Boston, USA:**
The D-Bateable IOM Report: A D-Lightful Perspective
*(25 + 5 min, Abstract No. 39)*

0.45 – 1.15 PM  **Round Table Discussion (chair: R. Vieth):**  Vitamin D and analogs: a new era in cancer prevention and treatment?

1.15 – 1.20 PM  **Closing Remarks:**  J. Reichrath, M. Friedrich

1.20 PM  **Lunch**